树突状细胞(DCs)是免疫反应的关键调节因子,在先天免疫和适应性免疫之间起作用。和DC功能的缺陷有助于多种疾病的发病机理。例如,癌症在DC活动有限的背景下发展,一些自身免疫性疾病是由DC依赖性抗原呈递引发的。因此,纠正异常的DC功能作为一种有前途的治疗范例,正如在过去二十年中积累的大量临床前和临床文献所证明的那样。然而,DC靶向方法的治疗潜力仍有待临床充分利用.这里,我们讨论了DC的独特特征,这些特征是DC靶向策略的高治疗潜力的基础,并批判性地分析了阻碍完全实现这一前景范式的障碍.
Dendritic cells (DCs) are key regulators of immune responses that operate at the interface between innate and adaptive immunity, and defects in DC functions contribute to the pathogenesis of a variety of disorders. For instance, cancer evolves in the context of limited DC activity, and some autoimmune diseases are initiated by DC-dependent antigen presentation. Thus, correcting aberrant DC functions stands out as a promising therapeutic paradigm for a variety of diseases, as demonstrated by an abundant preclinical and clinical literature accumulating over the past two decades. However, the therapeutic potential of DC-targeting approaches remains to be fully exploited in the clinic. Here, we discuss the unique features of DCs that underlie the high therapeutic potential of DC-targeting strategies and critically analyze the obstacles that have prevented the full realization of this promising paradigm.